Who is Martin Shkreli?

Martin Shkreli is an American investor and software founder who became one of the most disliked public figures in the United States after his company raised the price of a life-saving drug by more than 5,000% in 2015. Two years later, a jury convicted him of securities fraud in an unrelated hedge fund case.

He spent more than four years in prison before transferring to a halfway house in May 2022, ahead of his final release from federal custody that September. The government had taken his sole-copy Wu-Tang Clan record, a Picasso, and an Enigma machine, and a separate civil case stripped away the profits from the drug price increase.

By 2026, he occupies a strange position in finance. Barred for life from pharmaceuticals and from running a public company, he has rebuilt an audience through daily YouTube livestreams, a Substack, and a Bloomberg-style trading terminal. He is petitioning the Trump administration for a pardon, although clemency would not remove his civil pharmaceutical-industry ban.

Trackers list him near zero; one securities database still shows him at $99 million, and the honest answer sits between a large negative number and a modest private-equity bet on his own redemption.

Martin Shkreli's Background

Shkreli's route to infamy passed through Brooklyn public housing, Wall Street internships, a string of hedge funds, and two pharmaceutical companies whose pricing decisions made him a household name.

Early Life and First Hedge Funds

Martin Shkreli was born on 17 March 1983 in Brooklyn, New York, to working-class Albanian immigrant parents who worked as janitors. He earned a business degree from Baruch College in 2004 after interning at Jim Cramer's hedge fund while still a teenager.

He launched Elea Capital in 2006, which folded after a losing trade, then the MSMB Capital and MSMB Healthcare funds. The MSMB funds shorted biotech stocks while Shkreli publicly attacked the companies' science, an early version of the persona he still uses today.

Retrophin and the Daraprim Scandal

In 2011 he founded Retrophin, a biotech focused on rare diseases, and served as its CEO until the board removed him in 2014. He then started Turing Pharmaceuticals, which bought the rights to Daraprim, a decades-old antiparasitic used by HIV patients, and lifted its price from $13.50 to $750 per pill.

The increase triggered congressional hearings and a Federal Trade Commission antitrust case that outlived his criminal conviction and now defines his balance sheet, since the court found he schemed to block generic competition.

Conviction and Prison Sentence

Federal agents arrested Shkreli in December 2015 over conduct at MSMB and Retrophin, not Daraprim. Prosecutors showed he had lied to fund investors about losses and repaid them with Retrophin assets, and in 2017 a jury found him guilty on three counts covering securities fraud and conspiracy.

He received seven years plus a $7.36 million forfeiture order in 2018, lost his appeal in 2019, and spent part of his sentence in solitary confinement for running Vyera, formerly known as Turing Pharmaceuticals, from prison on a contraband phone. His supervised release ended in 2025.

Martin Shkreli's Net Worth

Most public trackers put Martin Shkreli's 2026 net worth at zero, and the real figure is arguably negative, because the $64.6 million disgorgement judgment from the FTC case exceeds any assets he is known to hold. His wealth peaked near $70 million before his arrest, a figure confirmed in court by federal prosecutors in 2017.

The current picture rests on a few documented inputs:

• The $64.6 million judgment: The January 2022 ruling in the FTC case required him to disgorge Daraprim profits and imposed a lifetime pharmaceutical ban. The Supreme Court declined his appeal in October 2024, making the debt final.
• Forfeited assets: His Retrophin shares, brokerage accounts, the Wu-Tang record, a Picasso, and an unreleased Lil Wayne project were seized or sold to satisfy the separate $7.36 million criminal forfeiture.
• Disclosed income: A 2023 probation filing showed him earning $2,500 a month consulting for a law firm while living with his sister in Queens, the only verified income figure since his release.
• DL Software equity: His co-founder stake in the company behind Godel Terminal is his most credible asset, though the startup's valuation has never been disclosed and the shares are illiquid.
• Media income: YouTube streams and Substack subscriptions generate cash flow that no public filing quantifies.
• Advisory income: Q/C’s SEC filing discloses a 12-month agreement with an LLC affiliated with Shkreli carrying $12,500 per month, or $150,000 annually, 212,500 restricted shares, warrants for 212,500 shares at a $5.097 exercise price, and quarterly vesting conditions.

We treat the near-zero estimates as the defensible baseline. Any headline suggesting he remains a millionaire has to explain how those assets would survive a final $64.6 million claim held by the FTC and seven state attorneys general.

Why Some Databases Still Show Him as Rich

Insider-trading databases such as GuruFocus list Shkreli's net worth near $99 million because they still attribute roughly 1.77 million Travere Therapeutics shares to him from Form 4 filings dated 2014, when the company was called Retrophin. Those holdings were forfeited or sold years ago to satisfy his criminal penalties.

Automated wealth trackers rarely process forfeiture orders, so figures for convicted executives can stay frozen at pre-conviction levels for a decade. Our estimate relies on court records rather than database snapshots.

What is Martin Shkreli Doing Now?

Shkreli has rebuilt a public career at the intersection of software, markets commentary, and biotech analysis, the three areas his bans do not reach. A July 2026 Bloomberg profile described him as back and unapologetic, shorting stocks and picking fights across finance.

DL Software and Godel Terminal

His main venture is DL Software, which he founded in 2016 under the name Gödel Systems and revived after prison. Its flagship product, Godel Terminal, sells market data and analytics for $996 per year and positions itself as a low-cost alternative to a Bloomberg Terminal seat costing over $30,000.

The company raised a $2 million pre-seed round in July 2024 led by dao5, Naval Ravikant, and Evolve Ventures, then closed a $5 million seed led by Infinitum in January 2026. DL also operates the Dr. Gupta AI health chatbot and reports millions of dollars in growing revenue, claims we cannot independently verify.

Q/C Technologies and Photonic Computing

In December 2025, he became a strategic advisor to Q/C Technologies (Nasdaq: QCLS), a micro-cap developing light-based processors, and later said he works there directly. He published a bull case for photonic computing in March 2026, arguing optical chips could eventually challenge Nvidia's dominance in AI hardware.

QCLS pivoted from pharmaceuticals to photonics only in late 2025, carries heavy losses on minimal revenue, and trades far below its 52-week high, so his involvement reads as a high-risk equity wager rather than a stable income source.

The Pardon Application

Shkreli formally filed for a presidential pardon in mid-2026, telling interviewers that talk of a mass clemency push tied to the country's 250th anniversary prompted the filing. He says he paid no lobbyist and wants relief mainly to re-enter the pharmaceutical industry.

The precedent is mixed. President Trump has already granted clemency to crypto convicts such as Binance founder CZ and Ross Ulbricht, yet a pardon would not erase Shkreli's FTC judgment or lifetime industry ban, which are civil measures outside the clemency power.

Martin Shkreli's Short Positions and Market Calls

Shkreli's most consequential financial act since prison has been a public campaign of short positions, announced across his podcast, X account, and livestreams. In December 2024, he disclosed he was shorting Strategy, then MicroStrategy, calling Michael Saylor's leveraged Bitcoin accumulation a bubble that could not end well.

The trade looked terrible through 2025 as MSTR rallied above $400, and he admitted the position was painful. The 2026 crypto downturn reversed the scoreboard, with Bitcoin dropping below $60,000 and MSTR hitting a two-year low near $92 in June while sitting on an estimated $10.6 billion in unrealized Bitcoin losses.

His target list extends well beyond Michael Saylor. He announced shorts on quantum computing names IonQ and Quantum Computing Inc in 2024, added Opendoor and Beyond Meat in 2025, and spent mid-2026 publicly questioning the trial data timeline at Sellas Life Sciences, echoing the biotech short activism of his MSMB years.

None of his position sizes are disclosed, so the profit and loss remains guesswork. What the record shows is direction, and on Bitcoin, Strategy, and the wider Bitcoin treasury company sector, his bearish thesis aged far better in 2026 than most commentators expected.

Martin Shkreli's Crypto History

Shkreli's own crypto ventures have ended badly for buyers. His Martin Shkreli Inu memecoin collapsed in 2022 after what he described as a hack, and his Druglike drug-discovery platform on Web3 rails faded without a product.

The DJT token episode remains the most notorious. In June 2024, he claimed on a Twitter Space that he created the Solana-based token with Barron Trump, after onchain investigator ZachXBT linked him to its deployment, and the token crashed after a large holder sale that August. Neither Donald Trump nor his family confirmed any connection, unlike the officially embraced token covered in our Trump memecoin explainer.

His crypto activity is now analytical rather than promotional. He treats Bitcoin as an overextended trade rather than an ideology, a stance that separates him from most figures in our net worth series.

The Wu-Tang Album Lawsuit

The strangest liability on Shkreli's ledger is litigation over an album he no longer owns. He paid $2 million in 2015 for "Once Upon a Time in Shaolin," the Wu-Tang Clan record pressed as a single physical unit, forfeited it after his conviction, and watched the government sell it to the crypto collective PleasrDAO for $4 million in 2021.

PleasrDAO sued him in June 2024 after he streamed the music to thousands of listeners and boasted online that he kept the MP3 files. In September 2025, a federal judge ruled the album can qualify as a trade secret, letting misappropriation and replevin claims proceed while dismissing several others.

Shkreli countersued in early 2026, arguing PleasrDAO's purchase of a copyright stake from RZA and Cilvaringz breached his original ownership rights. Whatever the outcome, the case adds legal costs and potential damages to a balance sheet that has no room for either.

Final Thoughts

Martin Shkreli's net worth is best understood as a debt with an option attached. The $64.6 million judgment makes his official position negative, yet his DL Software stake, his advisory equity, and his profitable 2026 short book give him plausible routes back to real wealth.

His trajectory now depends on decisions made by other people. A DL Software markup would hand him his first meaningful asset since 2015, and the PleasrDAO case could deepen the hole instead.

We find the contrast with his peers instructive. Sam Bankman-Fried sits in prison with his fortune legally erased, while Shkreli, five years past his release, is running the same playbook of concentrated bets and public provocation that built and destroyed his first $70 million.